NCT07195825View on ClinicalTrials.gov

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 9, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2031

Conditions
PD
Interventions
GENETIC

Injecting BBM-P002 into the bilateral putamen

BBM-P002 is an AAV-based gene therapy that delivers a therapeutic gene cassette into putamen for the treatment of Parkinson's Disease

Trial Locations (1)

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Xinzhi BioMed Co., Ltd.

INDUSTRY